Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease

Neurology

Volumn 49, Issue 4, 1997, Pages 1060-1065

  Guttman, Mark ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; LISURIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; DYSTONIA; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; VOMITING;

EID: 0030726156     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.4.1060     Document Type: Article

References (14)

1. Calne DB, Teychenne PF, Claveria LE, Eastman R, Grecnacre JK, Pétrie A. Bromocriptine in Parkinson's disease. BMJ 1974;4:442-444.
2. Olanow CW, Fahn S, Muenter MD, et al. A multicenter double-blind placebo controlled trial of pergolide as an adjunct to sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
3. Gopinathan G, Horowski R, Suchy I. Lisuride pharmacology and treatment of Parkinson's disease. In: Calne DB, ed. Drugs for the treatment of Parkinson's disease. Berlin, Heidelberg: Springer-Verlag, 1989:471-513.
4. Hutton JT, Koller WC, -Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996;46:10621065.
5. Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47: 785-788.
6. Quinn N. Drug treatment of Parkinson's disease. BMJ 1995; 310:575-579.
7. Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 1992;215:161-170.
8. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RN. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995;290:29-36.
9. Schilling JC, Adamus WS, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther 1992;51:541-548.
10. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.
11. Molho ES, Factor SA, Weiner WJ, et al. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease. J Neural Transm 1995;45:225-230.
12. Jette AM, Davies AR, Cleary PD, et al. The Functional Status Questionnaire: reliability and validity when used in primary care. J Gen Intern Med 1986;1:143-149.
13. EuroQol Group. EuroQol-a new facility for the measurement of health related quality of life. Health Policy 1990;12:199208.
14. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168.